US › Healthcare

Neumora Therapeutics, Inc. (NMRA)

US · Healthcare · Biotechnology

$0.75-3.00%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-43.1M

EPS

$-0.23

EPS estimate

$-0.23

EPS came in at -0.23 against a street estimate of -0.23 — a beat of 0.0%.

Key statistics

Market cap

$214.2M

Forward P/E

0.0

P/B

5.04

Book value

$0.24

EPS (TTM)

$-1.17

52-week high

$3.65

52-week low

$0.83

50-day MA

$1.57

200-day MA

$2.05

Beta

2.74

Analyst view

Analysts rate Neumora Therapeutics, Inc. a buy (3 buy, 5 hold, 0 sell out of 8) with an average price target of $6.14.

Shareholding

Insiders

23.25%

Institutions

60.09%

Largest institutional holders

Fund	Stake
Siren, L.L.C.	4.52%
SoftBank Group Corp	3.24%
Perceptive Advisors LLC	2.72%
MIC Capital Management UK LLP	2.37%
Vanguard Capital Management, LLC	2.07%
FMR Inc	1.86%
Wellcome Trust Ltd	1.76%
ICONIQ Capital, LLC	1.36%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Neumora Therapeutics, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.